IFLR: IFLR Asia-Pacific Awards 2024: Shortlist Revealed
January 30, 2024
The International Financial Law Review (IFLR) has named the initial public offering of Adlai Nortye Ltd. (NASDAQ: ANL), a global clinical-stage biotechnology company focused on the discovery and development of innovative cancer therapies, a finalist for the IFLR Asia-Pacific Awards 2024 in the category of Deal of the Year - Equity. O’Melveny & Myers LLP represented Adlai Nortye with respect to US law.
Read the full article here.